Skip to content

Glaukos GKOS EBITDA margin

EBITDA margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
34.4%+2.7pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
27.9%-2.8pp
AbbVie logo
AbbVieABBV
37.3%
Boston Scientific logo
Boston ScientificBSX
25.2%+1.6pp
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
20.9%-7.3pp
Exelixis logo
ExelixisEXEL
40.6%+6.2pp

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

Based on trailing twelve months.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's EBITDA margin?
Glaukos (GKOS) reported EBITDA margin of -28.5% in Q1 2026.
How has Glaukos's EBITDA margin changed year-over-year?
Glaukos's EBITDA margin decreased by 67.0% year-over-year, from -17.1% to -28.5%.
What is the long-term trend for Glaukos's EBITDA margin?
Over 5 years (2020 to 2025), Glaukos's EBITDA margin has grown at a -5.3% compound annual growth rate (CAGR), from -41.9% to -31.8%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.